October 30, 2015
Bayer’s Eylea approved for Myopic CNV
Eylea is now also approved for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV).
Pharmaceuticals, Biotechnology and Life Sciences
Eylea is now also approved for the treatment of visual impairment due to myopic choroidal neovascularization (myopic CNV).